Alpelisib in Intractable Non–Islet-Cell Tumor Hypoglycemia

This letter describes the use of alpelisib, a PI3 kinase inhibitor, to successfully treat severe hypoglycemia in a patient with intractable non–islet-cell tumor hypoglycemia.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 388; no. 20; pp. 1911 - 1913
Main Authors:	Cahn, Avivit, Shoyhet-Smoilovsky, Hagit, Fischer, Matan, Zick, Aviad, Riahi, Yael, Levenberg, Shulamit, Leibowitz, Gil
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 18-05-2023
Subjects:	1-Phosphatidylinositol 3-kinase Class I Phosphatidylinositol 3-Kinases - therapeutic use Clinical Medicine Clinical Medicine General Endocrinology Endocrinology General Glucagon Glucose monitoring Hematology Humans Hypoglycemia Hypoglycemia - drug therapy Hypoglycemia - etiology Insulin Insulin-like growth factors Kinases Musculoskeletal system Oncology Pancreatic cancer Paraneoplastic Syndromes - complications Phosphorylation Standard deviation Thiazoles - therapeutic use Treatments in Oncology Tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	This letter describes the use of alpelisib, a PI3 kinase inhibitor, to successfully treat severe hypoglycemia in a patient with intractable non–islet-cell tumor hypoglycemia.
Bibliography:	SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc2302935